MARKET

CPRX

CPRX

Catalyst Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.08
+0.03
+0.59%
After Hours: 5.05 -0.03 -0.59% 17:32 09/24 EDT
OPEN
5.02
PREV CLOSE
5.05
HIGH
5.15
LOW
4.960
VOLUME
960.16K
TURNOVER
--
52 WEEK HIGH
6.24
52 WEEK LOW
2.875
MARKET CAP
523.13M
P/E (TTM)
7.25
1D
5D
1M
3M
1Y
5Y
A Trio of Stock Picks With Growth Potential
GuruFocus News · 5d ago
Catalyst Pharmaceuticals To Participate At Oppenheimer Fall Healthcare Life Sciences & MedTech Summit On Sept. 21
Catalyst Pharmaceuticals, Inc. (Catalyst) (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients
Benzinga · 09/17 12:08
Catalyst Pharmaceuticals to Participate at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
CORAL GABLES, Fla., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medic...
GlobeNewswire · 09/17 12:03
3 Pharmaceutical Stocks Under $10 to Buy in September
StockNews.com · 09/16 13:21
Catalyst Pharmaceuticals's Return On Capital Employed Overview
According to Benzinga Pro, during Q2, Catalyst Pharmaceuticals (NASDAQ:CPRX) earned $15.84 million, a 61.6% increase from the preceding quarter. Catalyst Pharmaceuticals also posted a total of $36.37 million in sales, a 20.39% increase since Q1.
Benzinga · 09/15 16:04
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
CORAL GABLES, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medic...
GlobeNewswire · 09/10 12:03
Why Is Catalyst (CPRX) Down 12.6% Since Last Earnings Report?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/08 15:30
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
marketwatch.com · 09/03 20:46
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CPRX. Analyze the recent business situations of Catalyst Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CPRX stock price target is 8.30 with a high estimate of 11.00 and a low estimate of 6.50.
EPS
Institutional Holdings
Institutions: 196
Institutional Holdings: 87.96M
% Owned: 85.41%
Shares Outstanding: 102.98M
TypeInstitutionsShares
Increased
40
6.86M
New
21
1.19M
Decreased
56
8.80M
Sold Out
16
1.46M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Chairman/Chief Executive Officer/President/Director
Patrick McEnany
Chief Financial Officer/Vice President/Treasurer
Alicia Grande
Chief Operating Officer/Chief Scientific Officer
Steven Miller
Chief Compliance Officer
Brian Elsbernd
Vice President
Mary Coleman
Other
Jeffrey Del Carmen
Other
Gary Ingenito
Lead Director/Independent Director
Charles O'Keeffe
Director
Molly Harper
Independent Director
Philip Coelho
Independent Director
Richard Daly
Independent Director
Donald Denkhaus
Independent Director
David Tierney
No Data
  • All
  • Financials
  • Insiders
More
About CPRX
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company. The Company is focused on in-licensing, developing, and commercializing medicines for patients living with rare diseases. The Company is developing a pipeline of medicines for other rare diseases. The Company's product Firdapse Tablet, 10 mg, is used for the treatment of adults with Lambert-Eaton Myasthenic Syndrome (LEMS) patients (ages 17 and above) in the United States and Canada. Firdapse consists of the phosphate salt of amifampridine. It is developing a long-acting formulation of amifampridine phosphate. The Company's Firdapse is also developing clinical trials for the treatment of muscle-specific receptor tyrosine kinase-positive myasthenia gravis (MuSK-MG). Catalyst Pharmaceuticals Ireland, Ltd. is the subsidiary of the Company.

Webull offers kinds of Catalyst Pharmaceuticals Inc stock information, including NASDAQ:CPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CPRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CPRX stock methods without spending real money on the virtual paper trading platform.